Development and Validation of a Clinical Scoring System Predicting 30-Day Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

IF 6.3 2区 医学 Q1 RESPIRATORY SYSTEM
Respirology Pub Date : 2025-07-01 DOI:10.1111/resp.70071
Joong-Yub Kim, Jayoun Kim, Myeong Geun Choi, Min Jee Kim, Yun Hae Ahn, Nakwon Kwak, Jaeyoung Cho, Jinwoo Lee, Young Sik Park, Chang-Hoon Lee, Sang-Min Lee, Chul-Gyu Yoo, Jin Woo Song, Sun Mi Choi
{"title":"Development and Validation of a Clinical Scoring System Predicting 30-Day Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.","authors":"Joong-Yub Kim, Jayoun Kim, Myeong Geun Choi, Min Jee Kim, Yun Hae Ahn, Nakwon Kwak, Jaeyoung Cho, Jinwoo Lee, Young Sik Park, Chang-Hoon Lee, Sang-Min Lee, Chul-Gyu Yoo, Jin Woo Song, Sun Mi Choi","doi":"10.1111/resp.70071","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is a frequent and fatal complication of IPF, with highly variable individual outcomes that are challenging to predict.</p><p><strong>Methods: </strong>This study included patients (≥ 19 years) who met the diagnostic criteria for AE-IPF. The primary outcome was 30-day mortality following hospital admission. Data on commonly assessed parameters at the time of emergency room presentation or hospital admission were collected. Variable selection and scoring were performed using the LASSO method and multivariable logistic regression, and the resulting model was validated in an independent cohort.</p><p><strong>Results: </strong>The derivation and validation cohorts comprised 128 and 100 patients, respectively. The final model incorporated eight variables (points): age ≥ 69 years (1), smoking status (current smoker: 2, past smoker: 1), use of home oxygen (1), history of hospital admission for non-AE events within the past 6 months (1), body mass index < 18.5 or > 23 kg/m<sup>2</sup> (1), lymphocyte percentage < 19% (2), total protein < 6.5 g/dL (1) and lactate level ≥ 1.75 mmol/L (1). Patient scores were calculated by summing the points for each variable. This scoring system of total 10 points demonstrated good discrimination, with Harrell's C-statistics of 0.84 (95% confidence interval, 0.75-0.93) in the derivation cohort and 0.81 (95% confidence interval, 0.71-0.92) in the validation cohort, and performed well in predicting 2-week, 3-month and in-hospital mortality.</p><p><strong>Conclusion: </strong>We developed and validated a scoring system based on readily available clinical parameters that effectively stratified 30-day mortality risk in patients with AE-IPF, offering a practical tool for bedside prognosis.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/resp.70071","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is a frequent and fatal complication of IPF, with highly variable individual outcomes that are challenging to predict.

Methods: This study included patients (≥ 19 years) who met the diagnostic criteria for AE-IPF. The primary outcome was 30-day mortality following hospital admission. Data on commonly assessed parameters at the time of emergency room presentation or hospital admission were collected. Variable selection and scoring were performed using the LASSO method and multivariable logistic regression, and the resulting model was validated in an independent cohort.

Results: The derivation and validation cohorts comprised 128 and 100 patients, respectively. The final model incorporated eight variables (points): age ≥ 69 years (1), smoking status (current smoker: 2, past smoker: 1), use of home oxygen (1), history of hospital admission for non-AE events within the past 6 months (1), body mass index < 18.5 or > 23 kg/m2 (1), lymphocyte percentage < 19% (2), total protein < 6.5 g/dL (1) and lactate level ≥ 1.75 mmol/L (1). Patient scores were calculated by summing the points for each variable. This scoring system of total 10 points demonstrated good discrimination, with Harrell's C-statistics of 0.84 (95% confidence interval, 0.75-0.93) in the derivation cohort and 0.81 (95% confidence interval, 0.71-0.92) in the validation cohort, and performed well in predicting 2-week, 3-month and in-hospital mortality.

Conclusion: We developed and validated a scoring system based on readily available clinical parameters that effectively stratified 30-day mortality risk in patients with AE-IPF, offering a practical tool for bedside prognosis.

预测特发性肺纤维化急性加重期30天死亡率的临床评分系统的开发和验证。
背景和目的:特发性肺纤维化(IPF)急性加重(AE)是IPF的常见和致命并发症,具有高度可变的个体结局,难以预测。方法:本研究纳入符合AE-IPF诊断标准的患者(≥19岁)。主要终点为入院后30天死亡率。收集了在急诊室就诊或住院时常用评估参数的数据。采用LASSO方法和多变量logistic回归进行变量选择和评分,并在独立队列中对所得模型进行验证。结果:推导和验证队列分别包括128例和100例患者。最终模型纳入了8个变量(点):年龄≥69岁(1)、吸烟状况(当前吸烟者:2,既往吸烟者:1)、家庭吸氧(1)、过去6个月内非ae事件住院史(1)、体重指数23 kg/m2(1)、淋巴细胞百分比。我们开发并验证了一个基于现成临床参数的评分系统,该系统可以有效地对AE-IPF患者的30天死亡风险进行分层,为床边预后提供实用工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Respirology
Respirology 医学-呼吸系统
CiteScore
10.60
自引率
5.80%
发文量
225
审稿时长
1 months
期刊介绍: Respirology is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and clinically-relevant experimental respiratory biology and disease. Fields of research include immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology, physiology, paediatric respiratory medicine, clinical trials, interventional pulmonology and thoracic surgery. The Journal aims to encourage the international exchange of results and publishes papers in the following categories: Original Articles, Editorials, Reviews, and Correspondences. Respirology is the preferred journal of the Thoracic Society of Australia and New Zealand, has been adopted as the preferred English journal of the Japanese Respiratory Society and the Taiwan Society of Pulmonary and Critical Care Medicine and is an official journal of the World Association for Bronchology and Interventional Pulmonology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信